Impfprophylaxe gegen ETEC-Reisediarrhoe und Cholera: Ist sie sinnvoll und für wen?

Zusammenfassung

Die Reisediarrhoe ist die häufigste Erkrankung bei Fernreisen und wird besonders durch Enterotoxin-bildende Escherichia coli-Stämme (ETEC) hervorgerufen. Die Cholera kommt in einigen tropischen Gebieten endemisch vor, bei Reisenden stellt sie jedoch nur ein marginales Problem dar. Der Pathomechanismus von ETEC ist dem von V. cholerae vergleichbar: Über die Aktivierung von cAMP kommt es zu einer nichtinflammatorisch- sekretorischen Diarrhoe. Da weder die Expositions- noch eine medikamentöse Prophylaxe Diarrhoeepisoden komplett verhindert, kann die Immunprophylaxe eine Alternative darstellen. In Form einer Konsensusempfehlung sehen deutschsprachige Tropen- und Reisemediziner in begründeten Fällen eine Indikation für die Choleraimpfung (Helfer in Flüchtlingslagern, Erfüllung von Einreisebestimmungen). Die ETEC Schutzkomponente kann bei definierten Risikogruppen (fehlende Magensäurebarriere, Immunsupprimierte, chronisch entzündliche Darmerkrankungen etc.) Anlass für die Impfung sein.

Summary

Travellers’ diarrhea is the commonest disease contracted on foreign travel and is most commonly caused by enterotoxin genic E. coli (ETEC). Cholera is endemic in several tropical countries, but it is only a marginal problem for travellers.

The pathological mechanism of ETEC is comparable to that of V. cholerae. Noninflammatory secretory diarrhea occurs via the activation of cAMP. Since neither exposure nor medical prophylaxis can completely prevent episodes of diarrhea, immunological prophylaxis can be an alternative. A Consensus Report by German experts on tropical and travel medicine has recommended that in certain cases (e. g. workers in refugee camps or to comply with conditions) cholera immunization may be indicated. The ETEC prophylactic component may be an indication for immunization of clearly defined groups at risk (absent gastric secretion barrier; immunocompromised state, inflammatory bowel disease).

ETEC-Reisediarrhoe - Cholera

travellerŽs diarhea - cholera

Literatur

• 1 Al-Abri S S, Beeching N J, Nye F J. TravellerŽs diarrhoea.  Lancet Infect Dis. 2005;  5 349-360
• 2 Albert M J, Siddique A K, Islam M S. et al . Large outbreak of clinical cholera due to Vibrio cholerae non-01 in Bangladesh.  Lancet. 1993;  341 704
• 3 Clemens J D, Sack D A, Harris J R. et al . Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial.  J Infect Dis. 1988;  158 372-377
• 4 Clemens J D, Sack D A, Harris J R. et al . Field trial of oral cholera vaccines in Bangladesh.  Lancet. 1986;  II 124-127
• 5 DuPont H L, Jiang Z D, Okhuysen P C. et al . A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelersŽ diarrhea.  Ann Int Med. 2005;  142 805-812
• 6 DuPont H L. Diarrhoeal disease: current concepts and future challenges. Antimicrobial therapy and prophylaxis.  Trans Roy Soc Trop Med Hyg. 1993;  87 31-34
• 7 Ericsson C D. TravellersŽ diarrhoea.  Int J Antimicrob Agents. 2003;  21 116-124
• 8 Hakanen A, Jousimies-Somer H, Siitonen H, Huovinen P, Kotilainen P. Fluoroquinolone resistance in Campylobacter jejuni isolates in travelers returning to Finland: association of ciprofloxacin resistance to travel destination.  Emerg Infect Dis. 2003;  9 267-270
• 9 Herwaldt B L, de Arroyave K R, Roberts J M, Juranek D D. A multiyear prospective study of the risk factors for and incidence of diarrheal illness in a cohort of Peace Corps volunteers in Guatemala.  Ann Int Med. 2000;  132 982-988
• 10 Hoge C W, Gambel J M, Srijan A, Pitarangsi C, Echeverria P. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years.  Clin Infect Dis. 1998;  26 341-345
• 11 Holmgren J, Bergquist C. New and improved vaccines against cholera. 3rd ed New York: Marcel Decker In MM Levine et al. (ed.): New Generation Vaccines 2004: 499-518
• 12 Jiang Z D, Okhuysen P C, Guo D C. et al . Genetic susceptibility to enteroaggregative Escherichia coli diarrhea: polymorphism in the interleukin-8 promotor region.  J Infect Dis. 2003;  188 506-511
• 13 Nataro J P, Kaper J B. Diarrheagenic Escherichia coli.  Clin Microbiol Reviews. 1998;  11 142-201
• 14 Neal K R, Scott H M, Slack R C, Logan R F. Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study.  BMJ. 1996;  17 414-415
• 15 Peltola H, Siitonen A, Kyrönseppä H. et al . Prevention of travellersŽdiarrhoea by oral B-subunit/whole-cell cholera vaccine.  Lancet. 1991;  338 1285-1289
• 16 Rendi-Wagner P, Kollaritsch H. Drug prophylaxis for travelers’ diarrhea.  Clin Inf Dis. 2002;  34 628-633
• 17 Robert Koch-Institut. Reiseassoziierte infektionsbedingte Erkrankungen im Jahr 2004.  Epid Bull. 2005;  35 317-324
• 18 Robins G W, Wellington K. Rifaximin: A review of its use in the management of travellerŽs diarrhoea.  Drugs. 2005;  65 1697-1713
• 19 Sack D A, Sack R B, Nair G B, Siddique A K. Cholera.  Lancet. 2004;  363 223-233
• 20 Scerpella E G, Sanchez J L, Mathewson J J. et al . Safety, immunogenicity, and protective efficacy of the whole-cell/recombinant B subunit (WC/rBS) oral cholera vaccine against travelersŽ diarrhea.  J Travel Med. 1995;  2 22-27
• 21 Sixma T K, Kalk K H, van Zanten B A. et al . Refined structure of Escherichia coli heat-labile enterotoxin, a close relative of cholera toxin.  J Mol Biol. 1993;  230 890-918
• 22 Sonnenburg J L, Angenent L T, Gordon J I. Getting a grip on things: how do communities of bacterial symbionts become established in our intestine?.  Nat Immunol. 2004;  5 569-573
• 23 Steinsland H, Valentiner-Branth P, Gjessing H K, Aaby P, Molbak K, Sommerfelt H. Protection from natural infections with enterotoxigenic Escherichia coli: longitudinal study.  Lancet. 2003;  362 286-291
• 24 Steffen R, Castelli F, Nothdurft H D, Rombo L, Zuckerman J N. Vaccination against enterotoxigenic Escherichia coli, a cause of travelersŽ diarrhea.  J Travel Med. 2005;  12 102-107
• 25 Steffen R, Acar J, Walker E, Zuckerman J. Cholera: assessing the risk to travellers and identifying methods of protection.  Trav Med Inf Dis. 2003;  1 80-88
• 26 Steffen R. Rifaximin: a nonabsorbed antimicrobial as a new tool for treatment of travelers’ diarrhea.  J Travel Med. 2001;  (Suppl) 2) 8 S34-39
• 27 Steffen R, Collard F, Tornieporth N. et al . Epidemiology, etiology, and impact of travelerŽs diarrhea in Jamaica.  JAMA. 1999;  281 811-817
• 28 Svennerholm A ML, Savarino S J. Oral inactivated whole cell B subunit combination vaccine against enterotoxigenic Escherichia coli. 3rd ed New York: Marcel Dekker In MM Levine et al. (ed.) : New generation vaccines 2004: 737-750
• 29 Taylor D N, Connor B A, Shlim D R. Chronic diarrhea in the returned traveler.  Med Clin North Am. 1999;  83 1033-1052
• 30 Vila J, Vargas M, Ruiz J, Corachan M, JimenezDeAnta M T, Gascon J. Quinolone resistance in enterotoxigenic Escherichia coli causing diarrhea in travelers to India in comparison with other geographical areas.  Antimicrob Agents Chemother. 2000;  44 1731-1733
• 31 Von Sonnenburg F, Tornieporth N, Waiyaki P. et al . Risk and aetiology of diarrhoea at various tourist destinations.  Lancet. 2000;  356 133-134